{"id":61475,"date":"2024-11-08T12:06:07","date_gmt":"2024-11-08T12:06:07","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/11\/08\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/"},"modified":"2024-11-08T12:06:07","modified_gmt":"2024-11-08T12:06:07","slug":"axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/","title":{"rendered":"Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024"},"content":{"rendered":"<div>\n<p align=\"justify\">NEW YORK, Nov.  08, 2024  (GLOBE NEWSWIRE) &#8212; Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced eight presentations spanning its innovative portfolio of late-stage products and product candidates in psychiatry and neurology at NEI Congress 2024, being held Nov. 7 &#8211; Nov. 10, 2024, in Colorado Springs, Colorado.<\/p>\n<p align=\"justify\">Details for the presentations are as follows:<\/p>\n<p><strong><em>Major Depressive Disorder<\/em><\/strong><\/p>\n<p><strong>Title:<\/strong> AXS-05 (Auvelity\u00ae) in Major Depressive Disorder: Pooled Data from Two Six-Week Controlled Trials (GEMINI and ASCEND)<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Friday, Nov. 8, 3:35 \u2013 4:30 p.m. ET<br \/><strong>Lead Author:<\/strong> Craig Chepke, MD, SUNY Upstate Medical University<br \/><strong>Poster Number: <\/strong>101<\/p>\n<p><strong>Title:<\/strong> Effects of AXS-05 (Auvelity\u00ae) in Improving Anhedonia and Interest-Activity Symptoms of MDD and the Associated Improvements in Functional Impairment <br \/><strong>Presentation Date and Time:\u00a0<\/strong>Friday, Nov. 8, 3:35 \u2013 4:30 p.m. ET<br \/><strong>Lead Author:<\/strong> Roger McIntyre, MD, Professor of Psychiatry and Pharmacology at the University of Toronto<br \/><strong>Poster Number: <\/strong>27<\/p>\n<p><strong>Title:<\/strong> Real-World Treatment Experiences and Expectations by Symptom Severity in Patients with Major Depressive Disorder<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Friday, Nov. 8, 3:35 \u2013 4:30 p.m. ET<br \/><strong>Lead Author:<\/strong> Roger McIntyre, MD, Professor of Psychiatry and Pharmacology at the University of Toronto<br \/><strong>Poster Number: <\/strong>87<\/p>\n<p><strong>Title:<\/strong> Real-World AXS-05 (Auvelity\u00ae) Patient Characteristics in Major Depressive Disorder<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Friday, Nov. 8, 3:35 \u2013 4:30 p.m. ET<br \/><strong>Lead Author:<\/strong> Andrew Muzyk, MD, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC <br \/><strong>Poster Number: <\/strong>116<\/p>\n<p><strong><em>Alzheimer\u2019s Disease Agitation<\/em><\/strong><\/p>\n<p><strong>Title:<\/strong> Clinical Profile of AXS-05 in Treating Alzheimer\u2019s Disease-Related Agitation: Results from The Phase 2\/3 Development Program<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Friday, Nov. 8, 3:35 \u2013 4:30 p.m. ET<br \/><strong>Lead Author:<\/strong> Jeffrey Cummings, MD, ScD, Vice Chair of Research, UNLV Department of Brain Health<br \/><strong>Poster Number: <\/strong>25<\/p>\n<p><strong><em>OSA and Narcolepsy <\/em><\/strong><\/p>\n<p><strong>Title:<\/strong> Solriamfetol for Excessive Daytime Sleepiness in Patients with Narcolepsy and OSA Reporting Anxiety and Depression in the Real-World SURWEY Study<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Friday, Nov. 8, 3:35 \u2013 4:30 p.m. ET<br \/><strong>Lead Author:<\/strong> Ulf Kallweit, MD, Assistant Professor of Neurology at the University Witten\/Herdecke, Germany<br \/><strong>Poster Number: <\/strong>98<\/p>\n<p><strong><em>Cognition<\/em><\/strong><\/p>\n<p><strong>Title:<\/strong> Effects of Solriamfetol on Cognition in Obstructive Sleep Apnea with Excessive Daytime Sleepiness and Impaired Cognition in the SHARP Clinical Trial<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Friday, Nov. 8, 3:35 \u2013 4:30 p.m. ET<br \/><strong>Lead Author:<\/strong> Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, department of neurology, Johannes Gutenberg-University, Mainz, Germany<br \/><strong>Poster Number: <\/strong>103<\/p>\n<p><strong>Title:<\/strong> Effects of Solriamfetol on Cognition in Patients with Excessive Daytime Sleepiness Associated with Narcolepsy in the Real-World SURWEY Study<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Friday, Nov. 8, 3:35 \u2013 4:30 p.m. ET<br \/><strong>Lead Author:<\/strong> Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, department of neurology, Johannes Gutenberg-University, Mainz, Germany<br \/><strong>Poster Number: <\/strong>97<\/p>\n<p><strong>About Axsome Therapeutics<\/strong><\/p>\n<p align=\"justify\">Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SrUVmPOHRGSZc0Ucmxsj7nFyErdT1RzBjooLmZzupkTBmztgknJpE1B1T8nz0gfIJvuTdsdKZsBlKAurP8azvw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.axsome.com\">www.axsome.com<\/a>.<\/p>\n<p><strong>Forward Looking Statements<\/strong><\/p>\n<p align=\"justify\">Certain matters discussed in this press release are \u201cforward-looking statements\u201d. The Company may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company\u2019s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the continued commercial success of the Company\u2019s Sunosi\u00ae and Auvelity\u00ae products and the success of the Company\u2019s efforts to obtain any additional indication(s) with respect to solriamfetol and\/or AXS-05; the Company\u2019s ability to maintain and expand payer coverage; the success, timing and cost of the Company\u2019s ongoing clinical trials and anticipated clinical trials for the Company\u2019s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company\u2019s ability to fully fund the Company\u2019s disclosed clinical trials, which assumes no material changes to the Company\u2019s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company\u2019s ongoing clinical trials, and\/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (\u201cNDA\u201d) for any of the Company\u2019s current product candidates; the Company\u2019s ability to fund additional clinical trials to continue the advancement of the Company\u2019s product candidates; the timing of and the Company\u2019s ability to obtain and maintain U.S. Food and Drug Administration (\u201cFDA\u201d) or other regulatory authority approval of, or other action with respect to, the Company\u2019s product candidates, including statements regarding the timing of any NDA submission; whether issues identified by FDA in the complete response letter may impact the potential approvability of the Company\u2019s NDA for AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to the Company\u2019s special protocol assessment for the MOMENTUM clinical trial; the Company\u2019s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company\u2019s research and development programs and collaborations; the success of the Company\u2019s license agreements; the acceptance by the market of the Company\u2019s products and product candidates, if approved; the Company\u2019s anticipated capital requirements, including the amount of capital required for the continued commercialization of Sunosi and Auvelity and for the Company\u2019s commercial launch of its other product candidates, if approved, and the potential impact on the Company\u2019s anticipated cash runway; the Company\u2019s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company\u2019s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.<\/p>\n<p align=\"justify\"><strong>Investors:<\/strong><br \/>Mark Jacobson<br \/>Chief Operating Officer<br \/>(212) 332-3243<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S4cSIaVEQqGJWMg89n6dKEiZcnaDCoHSkIFwdZwjpfiSAUIsXQbaw01gGrpTiKnk4e1UvVMpzLc7VjeUt0Uxz_t6KWyACN1MQq53ltjoBr0=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"mjacobson@axsome.com\">mjacobson@axsome.com<\/a><\/p>\n<p align=\"justify\"><strong>Media:<\/strong><br \/>Darren Opland<br \/>Director, Corporate Communications<br \/>(929) 837-1065<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XbcpphPptSs66LFuHOLSi17CXElqblCiq3TttNJz0Sd1uWIfZSiPs7Mw_i3cF2ryvERKPj3AtQcpLpDvyuGvRKzCCYWKsOG3M5HupMdA5T0=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"dopland@axsome.com\">dopland@axsome.com<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MGQ2NjIyZjMtY2NmOS00Y2EwLTlhNzEtYmVjMmUxNDMzMDk0LTEwMzAxMzA=\/tiny\/Axsome-Therapeutics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) &#8212; Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced eight presentations spanning its innovative portfolio of late-stage products and product candidates in psychiatry and neurology at NEI Congress 2024, being held Nov. [&#8230;]\n","protected":false},"author":1,"featured_media":61476,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-61475","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) &#8212; Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-08T12:06:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/11\/Axsome-Therapeutics-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024\",\"datePublished\":\"2024-11-08T12:06:07+00:00\",\"dateModified\":\"2024-11-08T12:06:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/\"},\"wordCount\":1118,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/\",\"name\":\"Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-11-08T12:06:07+00:00\",\"dateModified\":\"2024-11-08T12:06:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/","og_locale":"en_US","og_type":"article","og_title":"Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024","og_description":"NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) &#8212; Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel","og_url":"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-11-08T12:06:07+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/11\/Axsome-Therapeutics-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024","datePublished":"2024-11-08T12:06:07+00:00","dateModified":"2024-11-08T12:06:07+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/"},"wordCount":1118,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/","url":"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/","name":"Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-11-08T12:06:07+00:00","dateModified":"2024-11-08T12:06:07+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/61475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=61475"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/61475\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/61476"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=61475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=61475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=61475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}